Oligopin Supplementation & Bone Turnover Markers & Antioxidant Changes in

Status Completed

Clinical Trial Summary

Osteoporosis fractures impose a significant economic burden on the health system. There is evidence that osteoporosis has a high prevalence in Iran (4.8% for men and 7.7% for women), and the frequency of osteopenia is 36.8% for men and 39.3% for women in Iran Accordingly, the prevention of osteopenia progression towards osteoporosis has been considered as an important issue in medicine. Bone is a dynamic tissue that is constantly being remodeled thus the equilibrium between bone formation and resorption done by simultaneously regulating osteoclasts and osteoblasts is important. Imbalance between bone deposition and resorption contributes to reducing bone mineral density and hence increasing the risk of osteoporosis

Recently, new therapies have been focused on use of medicinal herbs, especially phytochemicals. Among phytochemicals, phytonutrients, and especially polyphenols, can act both on osteoblast and on osteoclast.

Pine bark extract (oligopin) is a rich source of polyphenols that exerts strong antioxidant and anti-inflammatory activities. It has also beneficial effects on bone turnover based on in vitro studies and animal models. Investigators aimed to investigate the effects of oligopin on bone turnover markers and plasma and peripheral mononuclear cells oxidative stress in postmenopausal women with osteopenia in a double-blind randomized clinical trial. Participants are forty four women with osteopenia divided into two groups randomly (22, having oligopin, 150 mg, once daily, for 12 weeks). The 2nd group (22 women with osteopenia) receives the same amount of the placebo. At the first and the end of the study, blood sample are taken to measure in order to peripheral blood mononuclear cells isolation and plasma separation. The levels of bone alkaline phosphatase and carboxy terminal collagen type I in plasma oxidative stress markers such as total anti-oxidant capacity, malondialdehyde, and protein carbonyl were evaluated. Furthermore, oxidative stress will be evaluated in peripheral blood mononuclear cells by measurement of expression and activity of magnesium superoxide dismutase,catalase and Nuclear factor (erythroid-derived 2)-like 2.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03260803
Study type	Interventional
Source	Tehran University of Medical Sciences
Contact
Status	Completed
Phase	Phase 3
Start date	February 1, 2018
Completion date	March 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04754711` - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition	N/A
Active, not recruiting	`NCT05066477` - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women	N/A
Terminated	`NCT01902186` - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir	Phase 4
Not yet recruiting	`NCT01397838` - Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women	Phase 1
Completed	`NCT01439139` - Bone UltraSonic Scanner (BUSS): Validation Study	N/A
Completed	`NCT01222026` - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate	Phase 4
Completed	`NCT01152580` - Melatonin Osteoporosis Prevention Study	Phase 1
Completed	`NCT00789425` - Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women	Phase 2
Completed	`NCT00655681` - Prevention of Post Operative Bone Loss in Children	N/A
Completed	`NCT00463268` - Osteoporosis Prevention With Low Dose Alendronate	Phase 3
Completed	`NCT00798473` - Zoledronate for Osteopenia in Pediatric Crohn's	Phase 3
Active, not recruiting	`NCT00076050` - Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms	Phase 3
Completed	`NCT00226031` - Optimal Management of Women With Wrist Fractures	N/A
Enrolling by invitation	`NCT04752098` - A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method	N/A
Completed	`NCT04720833` - Effect of Dried Plum on Bone and Markers of Bone Status in Men	N/A
Recruiting	`NCT05541432` - Finding the Optimal Resistance Training Intensity For Your Bones	N/A
Active, not recruiting	`NCT05405894` - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Completed	`NCT05457036` - Evaluation of the Effect of Spry Belt Treatment on Bone Turnover Marker Profile	N/A
Completed	`NCT04040010` - The Effects of Bovine Colostrum in Bone Metabolism in Humans	N/A
Completed	`NCT02731820` - Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms